API | gefapixant

gefapixant Report issue

Small molecule Experimental

AACT ChEMBL PubChem

Active Ingredient History

NOW

Gefapixant, sold under the brand name Lyfnua, is a medication used to treat chronic (long-term) cough. It acts as an antagonist of the P2RX3 receptor. ^Wikipedia

Chemistry

SMILES: COc1cc(C(C)C)c(Oc2cnc(N)nc2N)cc1S(=O)(=O)N
InChIKey: HLWURFKMDLAKOD-UHFFFAOYSA-N
Mol. Mass: 353.4
ALogP: 1.21 Partition coefficient
ChEMBL Molecules:

gefapixant

None

More Chemistry

Pharmacology

Mechanism of Action:
- P2X purinoceptor 3 (Homo sapiens) ^UniProt
Multi-specific: Missing data
Black Box: No
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: No

af-219 | gefapixant

Organizations (10)

Research & Development (10)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (10)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (10)

Asthma (Phase 1)

Cough (Phase 3)

Cystitis, Interstitial (Phase 2)

Healthy Volunteers (Phase 1)

Hypertension (Phase 3)

Idiopathic Pulmonary Fibrosis (Phase 2)

Osteoarthritis, Knee (Phase 2)

Pain (Phase 2)

Renal Insufficiency (Phase 1)

Sleep Apnea, Obstructive (Phase 1)

Overview

Highest Phase: Phase 3
# of Trials: 27
# of Trial Organizations: 10

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue